Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06200207 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation

Name: A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation — clinical trial record (NCT06200207)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ATHENA

StatusActive, Not Recruiting

PhasePhase 3

SponsorNovo Nordisk A/S

Started2024-04-01

View on ClinicalTrials.gov ↗

The study is being done to see if ziltivekimab can be used to treat participants living with heart failure and inflammation. Participants will either get ziltivekimab (active medicine) or placebo (inactive substance that looks like the study medicine but does not contain any medicine). The treatment participants get is decided by chance. Participant's chance of getting ziltivekimab or placebo is the same. Ziltivekimab is not yet approved in any country or region in the world. It is a new medicine that doctors cannot prescribe. The study is expected to last for up to 1 year and 4 months.

Amendment history 2 changes detected by DataLookout

2026-08-01

Enrollment closed, study ongoing

2026-08-01

Trial sites reduced: 240 → 217 locations

Trial Details

NCT Number	NCT06200207
Lead Sponsor	Novo Nordisk A/S
Conditions	Heart Failure, Systemic Inflammation
Enrollment	680 participants
Start Date	2024-04-01
Primary Completion	2026-10-01 (estimated)
Study Completion	2027-01-08 (estimated)
Updated on ClinicalTrials.gov	2026-09-01